Is compounded tirzepatide legal in Georgia?
Yes, when a prescriber licensed in Georgia orders it for you and a pharmacy licensed to ship into Georgia makes it. It is not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients.
What ended is routine copying. The FDA declared the tirzepatide shortage over on December 19, 2024, and a federal appeals court upheld that on August 27, 2026; the grace period ended on March 5, 2025 for state-licensed (503A) pharmacies and on March 19, 2025 for outsourcing facilities (503B) (FDA). A pharmacy may still compound tirzepatide for one patient when the prescriber orders a change, such as a different formulation, that makes a significant difference for that patient. Georgia's own rule is similar: no compounding of "essentially copies of commercially available" drugs, except, among other cases, a change the prescriber orders for an individual patient (Rule 480-11-.02). Pharmacies must meet the stricter federal rule too.
Two 2026 federal steps matter too. On March 3, the FDA announced warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s, chiefly ads implying they were the same as FDA-approved drugs or hiding which pharmacy made them, and on April 30 it proposed barring outsourcing facilities from making tirzepatide from bulk ingredients (not final as of October 2026). At the Georgia Board of Pharmacy, the director of the Georgia Drugs and Narcotics Agency has noted that meeting Georgia's rules "does not automatically equate to compliance with federal law" (Board minutes, May 21, 2025).
You may also find a Georgia state PDF titled "Tirzepatide Products with Continued Patient Safety Concerns." It is a letter from Eli Lilly, Zepbound®'s maker, to the Georgia Board of Nursing dated April 1, 2025, asking the Board to warn nurse practitioners about compounded tirzepatide (the letter); it is a request, not a Georgia rule. The Board of Pharmacy accepted a 2026 Lilly letter "as informational only" (Board minutes, May 20, 2026).